Regulatory T Cell Content in the Bone Marrow Graft Does Not Predict the Occurrence of Acute GVHD

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 2, 2011, Pages 265-269

  Rosenzwajg, Michelle ^a,b   Dhédin, Nathalie ^b   Maury, Sébastien ^c   Bensimon, Gilbert ^a,b   Landau, Dan Avi ^a,d   Norol, Françoise ^b   Trébéden Negre, Hélène ^b   Uzunov, Madalina ^b   Vernant, Jean Paul ^a,b   Klatzmann, David ^a,b   Cohen, José L ^a,b  

^a SORBONNE UNIVERSITÉ   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c FACULTÉ DE MÉDECINE   (France)

^d YALE CANCER CENTER   (United States)

Author keywords

CD4+CD25+ regulatory T cells; Clinical study; Hematopoietic stem cell transplantation; Human

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; BONE MARROW TRANSPLANTATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; MALE; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION;

ACUTE DISEASE; ADOLESCENT; ADULT; ANTIGENS, CD4; BONE MARROW CELLS; BONE MARROW TRANSPLANTATION; CELL COUNT; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; HUMANS; INCIDENCE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SIBLINGS; T-LYMPHOCYTES, REGULATORY; YOUNG ADULT;

EID: 79251531634     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.07.024     Document Type: Article

References (21)

1. Kang S.M., Tang Q., Bluestone J.A. CD4+CD25+ regulatory T cells in transplantation: progress, challenges and prospects. Am J Transplant 2007, 7:1457-1463.
2. Cohen J.L., Trenado A., Vasey V., Klatzmann D., Salomon B.L. CD4(+)CD25(+) immunoregulatory T cells: new therapeutics for graft-versus-host disease. J Exp Med 2002, 196:401-406.
3. Taylor P.A., Lees C.J., Blazar B.R. The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood 2002, 99:3493-3499.
4. Magenau J.M., Qin X., Tawara I., et al. Frequency of CD4(+)CD25(hi)FOXP3(+) regulatory T cells has diagnostic and prognostic value as a biomarker for acute graft-versus-host-disease. Biol Blood Marrow Transplant 2010.
5. Cohen J.L., Boyer O. The role of CD4+CD25hi regulatory T cells in the physiopathogeny of graft-versus-host disease. Curr Opin Immunol 2006, 18:580-585.
6. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995, 15:825-828.
7. Rezvani K., Mielke S., Ahmadzadeh M., et al. High donor Foxp3-positive regulatory T-cell (TREG) content is associated with a low risk of GVHD following HLA-matched allogeneic stem cell transplantation (SCT). Blood 2006, 108:1291-1297.
8. Pabst C., Schirutschke H., Ehninger G., Bornhauser M., Platzbecker U. The graft content of donor T cells expressing gamma delta TCR+ and CD4+foxp3+ predicts the risk of acute graft versus host disease after transplantation of allogeneic peripheral blood stem cells from unrelated donors. Clin Cancer Res 2007, 13:2916-2922.
9. Wolf D., Wolf A.M., Fong D., et al. Regulatory T-cells in the graft and the risk of acute graft-versus-host disease after allogeneic stem cell transplantation. Transplantation 2007, 83:1107-1113.
10. Shevach E.M., McHugh R.S., Piccirillo C.A., Thornton A.M. Control of T-cell activation by CD4+ CD25+ suppressor T cells. Immunol Rev 2001, 182:58-67.
11. Blache C., Chauvin J.M., Marie-Cardine A., et al. Reduced frequency of regulatory T cells in peripheral blood stem cell compared to bone marrow transplantations. Biol Blood Marrow Transplant 2009, 16:430-434.
12. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol 2005, 23:5074-5087. Stem Cell Trialists' Collaborative Group.
13. Cutler C., Giri S., Jeyapalan S., Paniagua D., Viswanathan A., Antin J.H. Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis. J Clin Oncol 2001, 19:3685-3691.
14. Anderlini P., Champlin R.E. Biologic and molecular effects of granulocyte colony-stimulating factor in healthy individuals: recent findings and current challenges. Blood 2008, 111:1767-1772.
15. Morris E.S., MacDonald K.P., Hill G.R. Stem cell mobilization with G-CSF analogs: a rational approach to separate GVHD and GVL?. Blood 2006, 107:3430-3435.
16. Hoffmann P., Ermann J., Edinger M., Fathman C.G., Strober S. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med 2002, 196:389-399.
17. Edinger M., Hoffmann P., Ermann J., et al. CD4(+)CD25(+) regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 2003, 9:1144-1150.
18. Trenado A., Charlotte F., Fisson S., et al. Recipient-type specific CD4+CD25+ regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia. J Clin Invest 2003, 112:1688-1696.
19. Trenado A., Sudres M., Tang Q., et al. Ex vivo-expanded CD4+CD25+ immunoregulatory T cells prevent graft-versus-host-disease by inhibiting activation/differentiation of pathogenic T cells. J Immunol 2006, 176:1266-1273.
20. Hicheri Y., Bouchekioua A., Hamel Y., et al. Donor regulatory T cells identified by FoxP3 expression but also by the membranous CD4+CD127low/neg phenotype influence graft-versus-tumor effect after donor lymphocyte infusion. J Immunother 2008, 31:806-811.
21. Maury S., Lemoine F.M., Hicheri Y., et al. CD4+CD25+ Regulatory T cell depletion improves the graft-versus-tumor effect of donor lymphocytes after allogeneic hematopoietic stem cell transplantation. Sci Transl Med 2010, 2. 41ra52.